The Pharmacy Times® Mental Health Resource Center is a comprehensive resource for clinical news and expert insights on conditions that affect mood, thinking, and behavior, including clinical depression, bipolar disorder, schizophrenia, anxiety, and post-traumatic stress disorder.
January 21st 2025
The study found that internalizing and externalizing factors, brain maturation, and decreasing volumes of brain regions were linked to eating disorders.
Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Ph...
2.0 Credits / Neurology, Psychiatry
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Prescription Digital Therapeutics in Schizophrenia: A Managed Care Perspective on Advancements
2.0 Credits / Psychiatry
View More
Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia
3.0 Credits / Psychiatry
View More
Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies
1.0 Credit / Psychiatry
View More
Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption
November 26th 2021Ron Aung-Din, MD, the clinical medical advisor of Pyscheceutical, and Chad Harman, the CEO of Pyscheceutical, discuss a novel approach for administering psychedelics for the treatment of brain disorders that does not induce hallucinogenic effects.
Watch
Study: Subcutaneous Injectable Risperidone Improves Outcomes for Certain Patients With Schizophrenia
November 16th 2021The trial randomized patients to receive TV-46000 once monthly, TV-46000 once every 2 months, or placebo, and found that patients had improved outcomes on TV-46000 regardless of dosing schedule.
Read More
Expert: MDMA Is Very Likely to Be FDA-Approved for PTSD by the End of 2023
November 8th 2021Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses common themes or key points being raised in the field of psychedelic medicine at recent conferences.
Watch
Expert: Safety, Efficacy of Psilocybin May Be Negatively Impacted With Microdosing
October 29th 2021Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, on his recent presentations at Insight 2021 and the virtual Sana Symposium on psychedelic adverse effects and drug-drug interactions.
Watch
Study: Asthma, Hay Fever, Other Allergies Not Linked to Mental Health Traits
October 29th 2021Evidence of a causal relationship between the onset of allergic disease and mental health was limited, suggesting that the observational associations found were due to confounding or other forms of bias.
Read More
Psychedelic Drug in Early Stages of Development Could Have Potential for Postpartum Depression
October 28th 2021Nathan Bryson, PhD, chief scientific officer of Field Trip Health, said the company's new psychedelic compound, FT-104, could have potential uses in the treatment of postpartum depression.
Watch
Expert: How Social Media Impacts the Mental Health of Health Care Professionals
October 27th 2021Paula Durlofsky, PhD, a writer for the American Psychological Association's Device Management and Digital Intelligence committee discusses how social media has impacted the mental health of health care professionals in recent years, including the COVID-19 Pandemic.
Watch
Potential Drug-Drug Interactions With Psilocybin, MDMA, Ketamine
October 21st 2021Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses potential drug-drug interactions with psilocybin, MDMA, and ketamine to consider outside of interactions with psychiatric medications.
Watch